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MRGPRX2 Signaling in Mast Cells and Mastocytosis (Urticaria Pigmentosa)
Abstract
[1]
The neuropeptide substance P (SP) contributes to neurogenic inflammation, pain and atopic dermatitis in
mice through the activation of mast cells via MAS-related G protein-coupled receptor-B2 (MrgprB2). SP
also induces degranulation in human MCs through MRGPRX2, which is the human counterpart of
MrgprB2. MRGPRX2 contains six tyrosine residues, five located in transmembrane domains and one in
the receptor’s intracellular loop 2 (ICL2). Tyr279 in MRGPRX2’s seventh transmembrane domain contained
within the motif NPxxY is important for coupling to G proteins. In addition to G protein, selected
MRGPRX2 ligands also couple to β-arrestin-mediated signaling. However, the roles of MRGPRX2’s
tyrosine residues on G protein and β-arrestin-mediated signaling is unknown. To address this question,
we prepared cDNA encoding MRGPRX2 mutants Y67A, Y89A, Y113A, Y137A, Y222A or Y279A and
generated transient transfectants in RBL-2H3 cells. We found that while cells expressing wild-type (WT),
Y89A and Y222A responded normally to SP for Ca2+ mobilization and degranulation, mutants Y67A,
Y113A, Y137A and Y279A were unresponsive. To determine if G protein independent signaling mediates
β-arrestin recruitment. We cloned Y279A mutant into Tango vector and determined the ability to activate
β-arrestin by using SP. We found mutant Y279A failed to recruit β-arrestin. These findings suggest that
four tyrosine residues at MRGPRX2 show loss of function phenotype. Moreover, this is the first
demonstration that a single amino acid Tyr279 residue is involved in coupling to both G protein and βarrestin.
[2]
Mastocytosis is a condition that occurs when MCs accumulate in the skin and/or internal organs. It is
divided into two main categories systemic mastocytosis (SM) and cutaneous mastocytosis (CM).
Urticaria pigmentosa is the most common type of CM that is mainly presented as generalized small
macules and papules of a deep-brown color that affects the entire body. The etiology of the disease is
mainly due to a mutation of a KIT gene. However, the MCs’ activation mechanism is still unknown. To
address this question, we used immunohistochemistry (IHC) staining to confirm the presence of MCs.
After that, we utilized double immunofluorescence (IF) staining to detect MRGPRX2 signals. We found
that the number of MCs is higher in the diseased samples compared to the control. Moreover, we
detected MRGPRX2 signals in all MCs of patients with urticaria pigmentosa. Although the mechanism of
mastocytosis is still unknown, this is the first demonstration that MRGPRX2 is expressed at high level in
mast cells of patients of urticaria pigmentosa. These findings may help for further investigation about the
role of MRGPRX2 in this heterogeneous disease.
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CHAPTER 1

Introduction to MRGPRX2 Signaling in Mast
Cells and Mastocytosis

8

1.1 Mast Cells (MCs)
1.1.1. MCs development and function
Mast cells (MCs) are multi-functional granulocytes of hematopoietic origin that are rich in
histamine and tryptase. They circulate in the blood stream as immature precursors and
later differentiate and become mature in destination tissues including skin, intestinal
mucosa, and respiratory mucosa with the aid of stem cell factor (SCF) and other cytokines
[1-3]. In human, MCs are categorized into two subtypes based on protease content of
their secretory granules: MCT which contain tryptase only and are located in lungs and
gut; and MCTC which contain both tryptase and chymase and are found in connective
tissue such as the skin [4]. In rodents, connective tissue MCs (CTMCs) are equivalent to
MCTC while mucosal MCs (MMCs) are resemble MCT [5]. Historically, MCs are well known
for mediating allergic and hypersensitivity reactions. However, it now appears that these
cells play important roles in host defense against bacterial, viral and parasitic infections
and also contribute to autoimmune diseases, atherosclerosis, carcinogenesis.
Additionally, MCs served as a bridge between the immune and nervous systems [6-8].

1.1.2. Mast Cell activation
Mast cells can be activated through the classical immunoglobulin E (IgE) dependent
pathway. MCs express high affinity IgE receptor (FcεRI) on their cell surface. Activation
of MCs occurs when antigen attaches to IgE bound to FcεRI. This mechanism is well
studied, while less is known about activation of MCs via the IgE independent pathway.
The latter activation can be through different receptors such as G-protein coupled

9

receptors (GPCRs) [9,10]. Recently, a Novel GPCR was discovered known as Masrelated GPCR-X2 (MRGPRX2), which contributes to various physiological as well as
pathological responses [8,10,11].

1.1.3. Mast cells and nervous system
Mast cells are found in close proximity to nerve endings at multiple sites including the
skin, intestinal mucosa, and lungs [12]. Different MC-derived mediators such as,
histamine, serotonin and tryptase are able to activate sensory neurons. On the other
hand, multiple neuropeptides including substance P (SP), neuropeptides Y and calcitonin
gene-related peptide (CGRP) activate MCs to release histamine [10]. Both MCs and
neurons interact in a bi-directional way to promote several physiological and
immunological events. Sensory nerve endings can be stimulated by MC-derived
mediators such as histamine and tryptase leading to the release of different
neuropeptides such as substance P, which in turn, induce additional MC activation [7,13].
Many studies showed close relationship between MCs and nerve endings in neurogenic
inflammation, which is exemplified by degranulation of MCs in response to SP [10]. Thus,
MC–nerve interaction has been suggested as a main contributor in the pathogenesis of
neurogenic inflammation and pain [7]. Therefore, the relationship between MCs and
nerves are both anatomical and functional [7].
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1.1.4. Mast cells and Substance P
Substance P (SP) is a potent neuropeptide that can be released from neuronal and nonneuronal cells, including immune cells. The release of SP in the central and peripheral
nervous system has a principal role in stress response, neuro-inflammation and
transmitting pain signals [14,15]. MC secretory granules contain mediators such as
histamine, and tryptase that interact with their specific receptors on sensory nerve
endings, causing the release of neuropeptides, including SP [16,17]. Subsequently, SP
released from nerve endings can induce further MC activation, resulting in the release of
various proinflammatory cytokines, chemokines and as well as the recruitment of innate
immune cells [18]. The release of SP and other neuropeptide induce the activation of MCs
leading to several events including arteriolar vasodilation, hyperemia, and recruitment of
other immune cells [7]. Previously, neurokinin-1 receptor (NK-1R) was thought to be
responsible for MC activation by SP, due to its proximity as well as its functional role in
pain pathways. However, a recent study showed that SP may bind to MRGPRX2 which
leads to activation and degranulation of MCs independent of NK-1R [18].
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1.2 Mas-related G protein-coupled receptor X2 (MRGPRX2)
1.2.1. What is MRGPRX2?
G protein-coupled receptors (GPCRs) are considered one of the largest and most
diverse families of proteins that mainly act as mediators to transduce extracellular
stimuli into intracellular signals [19,20]. Moreover, crucial cellular functions such as cell
proliferation, development, survival, and metabolism can be controlled by this family [8].
GPCRs share a common structure comprised of seven transmembrane (TM) helices
that play a major role in transmitting signals through the cell membrane (Fig 1A). The
TM domains are connected by three extracellular loops (ECL1-3) and three intracellular
loops (ICL1-3). Binding of the ligand occurs through the ECL which includes Nterminus. On the other hand, the ICL that includes the C-terminus is responsible for Gprotein coupling [21,22].

Mas-Related G-Protein Coupled Receptors (MRGPRs) are members of the GPCR
family which include many genes in humans and rodents [23]. In humans, four genes
have been identified MRGPR X1-X4, while in mice, the MRGPR family is bigger. It
contains MrgprA (A1–A10), MrgprB (B1–B5, B8), MrgprC (C11), MrgprD, MrgprE,
MrgprF, MrgprG, and MrgprH genes [8]. Unique features of MRGPRX2 that differentiate
it from other GPCRs include their presence both on plasma membrane and intracellular
sites along with their selective expression in MCs [8].
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1.2.2. MrgprB2 is the mouse ortholog of human MRGPRX2
In mice, there are more than 20 potential MRG GPCR coding genes, which making it
difficult to recognize the mouse ortholog of human MRGPRX2. McNeil et al. [24], utilized
stringent reverse transcription polymerase chain reaction (RT-PCR) to evaluate mouse
peritoneal MCs (PMCs) and he found that these cells express messenger RNA only for
MrgprB2. Moreover, the same group tested mutated MrgprB2 for Ca 2+ mobilization and
histamine release to demonstrate a normal IgE dependent response. However, PMC of
the same mouse showed a significant reduction in Ca2+ mobilization and histamine
release in response to the ligands that are known to activate human MCs through
MRGPRX2 such as SP and compound 48/80 [24] These results suggest that MrgprB2 is
the mouse ortholog of human MRGPRX2. MRGPRX2 and its ortholog MrgprB2 are
expressed in MCTC and CTMCs, respectively. It is usual to share similar features.
However, they differ with respect to the concentrations of agonists needed for their
activation [8].

1.2.3. MRGPRX2 and SP
MRGPRX2 is expressed in MCTC and neuropeptides SP, VIP, and compound 48/80 can
activate and degranulate MCs via this receptor [8,18,25]. Substance P induces dosedependent degranulation in human MCTC and Ca2+ mobilization in human embryonic
kidney (HEK293) cells stably expressing MRGPRX2 [25]. This indicates that MRGPRX2
plays a key role in degranulation of MCTC. Moreover, transfected rat basophilic (RBL2H3) cells were utilized to confirm the specificity of SP for MRGPRX2 over MRGPRX1 to
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activate MCs and induce degranulation [26]. Fujisawa et al. [27] used lentiviral small
hairpin RNA (shRNA)-mediated knockdown of MRGPRX2 expression to examine SPinduced MC degranulation. They found significant inhibition of SP-induced MC
degranulation, while a specific inhibitor of NK-1R (CP-96345) does not inhibit SP-induced
MC degranulation. These outcomes suggest that although both NK-1R and MRGPRX2
are expressed in MCTC, SP utilizes MRGPRX2 to promote G protein-dependent MC
degranulation [18].

1.2.4. MRGPRX2 activation and regulation
Receptor desensitization and internalization are the main regulatory mechanisms
involved in GPCR signaling. Activated GPCRs are phosphorylated by a group of
serine/threonine protein kinases known as G protein coupled receptor kinases (GRKs)
with subsequent recruitment of β-arrestin, which results in desensitization and
internalization of the receptors [28,29]. Initially, this pathway was considered for its role
in GPCR desensitization, endocytosis, and internalization. However, it also exhibited an
important role in G protein–independent downstream signaling for various cell functions
such as cell migration, growth, and differentiation [30]. The favored agonists of G protein–
or -arrestin–mediated signaling pathways downstream of GPCRs are referred to as
“biased agonism”. Whereas agonists that activate both pathways are known as “balanced
agonists” [31].

14

1.3. Mastocytosis
1.3.1. Definition and types
Mastocytosis is a disorder that occurs when MCs accumulate in the skin and/or internal
organs such as the liver, spleen, bone marrow, and small intestines [32,33]. Based on the
anatomical accumulation of MCs, it is divided into mastocytosis in the skin (MIS) or
cutaneous mastocytosis (CM) where the disease is limited to the skin. In contrast to a
more aggressive variant known as systemic mastocytosis (SM) where MCs accumulated
in the internal organs as well as in the skin [33]. Cutaneous mastocytosis occurs mainly
in pediatric patients with the majority experiencing disease-onset within the first two years
of life that spontaneously regress with age. Systemic mastocytosis is more common in
adult patients and is characterized by persistent multi-organ involvement. In general, CM
has a favorable prognosis. However, patients with SM show variable prognoses ranging
from normal life expectancy to severely debilitating courses [32].

1.3.2. Etiology and pathogenesis
Mast cells are derived from hematopoietic stem cells. They circulate in the blood stream
as immature precursors, then migrate to peripheral tissue where they mature and become
differentiated MCs [1,3,30] . Mature MCs exist in tissue in proximity to blood vessels,
nerve endings and glandular structures. Furthermore, they are predominant in the skin,
gastrointestinal tract, and respiratory mucosa [1-3]. In addition to melanocytes,
hematopoietic progenitor cells, and germ cells, MCs express the KIT gene, a
transmembrane tyrosine kinase receptor for stem cell factor (SCF) [34]. The interaction
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between KIT and its ligand, SCF, plays a fundamental role in regulating MC proliferation,
maturation, adhesion, chemotaxis, and survival [33,35].

In most cases of SM, the accumulated MCs have a mutation in the KIT gene [35]. Longley
et al. showed substitution of the amino acid valine (Val) for aspartic acid (ASP) in position
816 (D816V) of the phosphotransferase domain that result in constitutive activation of the
mutated KIT gene [35]. The D816V mutation, has been detected in a majority of adult SM
cases. Additional but less common mutations have been identified resulting in V560G,
D815K, D816Y, insVI815-816, D816F, D816H, and D820G substitutions [33,36]. GarciaMontero et al. showed that SM cases with poor prognosis and severe systemic disease
phenotype are associated with mutation of undifferentiated hematopoietic progenitor
cells. On the other hand, mutations that target mature MCs showed a milder presentation
of the disease [36].

1.3.3. Classification of mastocytosis

Various classification systems have been developed by the World Health Organization
(WHO) to classify mastocytosis. The first was published in 2001, then later modified in
2008, and more recently, in 2016, an updated classification was adapted. The basic
notion of the earlier WHO classification and the related split into CM, SM, and localized
MC tumors are still valid and have been applied in the recent version of the WHO
classification [37,38]. The cutaneous form of the disease in CM is divided into 3 subtypes;
maculopapular CM, also called urticaria pigmentosa, diffuse cutaneous mastocytosis,
and localized mastocytoma of the skin. As mentioned earlier, a majority of CM cases
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affect children are associated with a good prognosis [39]. In contrast, most SM cases
develop in adult patients. SM is divided into indolent SM (ISM), smoldering SM (SSM),
SM with an associated hematologic (non-MC lineage) neoplasm (SM-AHN), aggressive
SM (ASM), and MC leukemia (MCL) [Table 1] [32]. The major SM criterion is the multifocal
clustering of MCs (at least 15 MCs/cluster) in 1 or more visceral organs [32]. There are
four minor SM diagnostic criteria including an abnormal morphology of MCs, expression
of CD2 and/or CD25 in MCs, an activating mutation at codon 816 of KIT (most frequently
KIT D816V) in extracutaneous tissues, and a persistent serum tryptase concentration of
> 20 ng/mL [Table 2]. To diagnose a patient with SM, either the major and at least one
minor criterion or 3 minor criteria should be met [32,37,38]
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CHAPTER 2

The Role of Tyrosine Residues in MRGPRX2
on G-Protein and -arrestin-Mediated Signaling
in Response to Substance P
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Abstract
The neuropeptide substance P (SP) contributes to neurogenic inflammation, pain and
atopic dermatitis in mice through the activation of mast cells via MAS-related G proteincoupled receptor-B2 (MrgprB2). SP also induces degranulation in human MCs through
MRGPRX2, which is the human counterpart of MrgprB2. MRGPRX2 contains six
tyrosine residues, five located in transmembrane domains and one in the receptor’s
intracellular loop 2 (ICL2). Tyr279 in MRGPRX2’s seventh transmembrane domain
contained within the motif NPxxY is important for coupling to G proteins. In addition to G
protein, selected MRGPRX2 ligands also couple to β-arrestin-mediated signaling.
However, the roles of MRGPRX2’s tyrosine residues on G protein and β-arrestinmediated signaling is unknown. To address this question, we prepared cDNA encoding
MRGPRX2 mutants Y67A, Y89A, Y113A, Y137A, Y222A or Y279A and generated
transient transfectants in RBL-2H3 cells. We found that while cells expressing wild-type
(WT), Y89A and Y222A responded normally to SP for Ca2+ mobilization and
degranulation, mutants Y67A, Y113A, Y137A and Y279A were unresponsive. To
determine if G protein independent signaling mediates β-arrestin recruitment. We
cloned Y279A mutant into Tango vector and determined the ability to activate β-arrestin
by using SP. We found mutant Y279A failed to recruit β-arrestin. These findings suggest
that four tyrosine residues at MRGPRX2 show loss of function phenotype. Moreover,
this is the first demonstration that a single amino acid Tyr279 residue is involved in
coupling to both G protein and β-arrestin.
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1. Introduction
MRGPRX2 contains six tyrosine (Tyr) residues, 2x42 and 2x64 both located in
transmembrane domain-2 (TM2), 3x36 located in TM3, 6x34 located in TM6, 7x45 located
in TM7, and finally 34x53 that is located in ICL2. In this GPCR numbering system, the
first number indicates the TM domains (1–7) and the second number implies the residue
position relative to the most conserved position, which is assigned the number 50 [40].
Amino acids at these positions in MRGPRX2 were identified from the GPCR database
(GPCRdb www.gpcrdb.org).

Samama et al. elucidated the importance of receptor mutagenesis in understanding
different mechanisms of GPCRs activation [41]. Conserved tyrosine residue may act as
a sequestration signal in many GPCRs in response to agonist stimulation [42]. Barak et
al. [42] showed mutation of the tyrosine residue caused agonist-induced sequestration in
a β2-adrenergic receptor (β2-AR). In contrast, Laporte et al. [43] replaced Tyr302 located
in TM7 of human angiotensin II receptor type I with (Y302F) or (Y302A) and showed no
effect on receptor internalization. Nonetheless, it may play a role in transmembrane
signaling [43]. In agreement, Choi et al., [44] showed that substitution of Tyr by Alanine
(Ala) in TM5 (Y219A) of β2-AR stimulate G protein biased signaling and induce G protein
activation. In the same study, they presented the inability of the variant (Y219A) to recruit
and internalized β-arrestin is mainly due to reduced phosphorylation by GPCR kinase
(GRK).
Hence, the substitution of Tyr219 by Ala (Y219A) may disturb the balance, causing a
conformational change relative to from that of the wild-type receptor [44]. In MRGPRX2,
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Tyr residue at position 7x53 plays an important role in receptor conformational changes
leading to receptor activation. Recently, it has been shown that Tyr279 In MRGPRX2’s
seventh TM contained within the motif NPxxY is important for coupling to G protein [45].
Moreover, selected MRGPRX2 ligands also couple to β-arrestin-mediated signaling.
However, no study has been conducted to determine the role of MRGPRX2’s Tyr residues
on both G-protein and β-arrestin signaling pathways. Thus, we decided to address this
question.

2. Research Aim
- To determine if mutations of tyrosine residues alter the MRGPRX2-mediated response
to SP.
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3. Materials and Methods
3.1 Materials
All cell culture reagents were purchased from Invitrogen (Gaithersburg, MD, USA).
Amaxa transfection kit (Kit V) was purchased from Lonza (Gaithersburg, MD, USA). Q5
Site-Directed Mutagenesis Kit was from New England BioLabs (Ipswich, MA). Substance
P (SP) was from AnaSpec (Fremont, CA, USA). Pertussis toxin (PTx) was from List
Biological Laboratories (Campbell, CA, USA). p-nitrophenyl-N-acetyl-β- D-glucosamine
(PNAG) was from Sigma-Aldrich (St. Louis, MO, USA). Fura-2 acetoxymethyl ester was
from Abcam (Cambridge, MA, USA). PE-conjugated anti-MRGPRX2 antibody was from
BioLegend (San Diego, CA, USA). MRGPRX2 plasmid encoding hemagglutinin (HA)tagged human MRGPRX2 in pReceiver-MO6 vector was obtained from GeneCopoeia
(Rockville, MD, USA).

3.2. Cell Culture
Rat basophilic leukemia (RBL-2H3) cells were maintained as monolayer cultures in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), l-glutamine (2 mM), penicillin (100 IU/mL), and streptomycin (100 μg/mL)
at 37 ◦C in presence of 5% CO2.

3.3. Site-directed Mutagenesis
Q5 site-directed mutagenesis kit (New England BioLabs, Ipswich, MA, USA) was used to
generate MRGPRX2 variants. DNA sequencing (Penn Genomics Analysis Core,
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Philadelphia, PA, USA) was performed to confirm nucleotide sequences. The following
List exhibited forward and reverse primers that were used.
Y67A: Forward: 5’-CTTCTCTGTCGCCGTCCTCAGCCTGGCCG-3’
Reverse: 5’-GCGTTCCTGCGCATGCGG-3’;
Y89A: Forward: 5’-TTGCCTGGTGGCCCTCAGTAAC-3’
Reverse: 5’-TTTATAATCTGGAAGCAGAG-3’;
Y113A: Forward: 5’-GACCTGTGCCGCCCTTGCAGGC-3’
Reverse: 5’-ATCACAGTGGTGAAGAAGC-3’;
Y137A: Forward: 5’-GCCCATCTGGGCTCGCTGCCGC-3’
Reverse: 5’-CACAGGACGGACAGGCAG-3’;
Y222A: Forward: 5’-GACCAGGCTGCCCCTGACCATCCTG-3’
Reverse: 5’-AGTGGCAGACCCCTGGAG-3’;
Y279A: Forward: 5’-CCCCATCATTGCCTTCTTCGTGG-3’
Reverse: 5’-TTGGCACTGCTGTTAAGAG-3’
MRGPRX2-Tango and Y279A-Tango: designed and provided by the Penn Genomic
Analysis Core, Philadelphia, PA

3.4. Transfection of RBL Cells Transiently Expressing MRGPRX2/Variants

RBL-2H3 cells were transfected with cDNA encoding MRGPRX2 or its variants as
described previously [9]. Briefly, cells (2 × 106) were transfected with 2.0,1.0, 0.75, and
0.5 μg of HA-tagged plasmid using the Amaxa Nucleofector Device and Amaxa Kit V
according to the manufacturer’s protocol. After transfection, cells were cultured for 16-20
hours before use.
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3.5. Degranulation Assay
The degranulation was measured by β-hexosaminidase release as described previously
[9]. Briefly, transfected RBL-2H3 cells (5 × 104 cells per well) were seeded into a 96-well,
white, clear-bottom cell culture plate and incubated overnight in a 37◦C incubator with 5%
CO2. Experimental groups were stimulated with SP (1 μM ) for 30 min at 37◦C. Cells
without treatment were designated as controls. To determine the total β-hexosaminidase
release, unstimulated cells were lysed in 50 μL of 0.1% Triton X-100. Aliquots (20 μL) of
supernatants or cell lysates were incubated with 20 μL of 1 mM p-nitrophenyl-N-acetyl-βD-glucosamine (PNAG) for 1 h at 37◦C. The reaction was stopped by adding 250 μL of
stop buffer (0.1 M Na2CO3/0.1 M NaHCO3). The β-hexosaminidase release was
assessed by measuring absorbance at 405 nm using Versamax microplate
spectrophotometer (Molecular Devices, San Jose, CA, USA).

3.6. Calcium Mobilization Assay
Calcium mobilization assay was used as described previously [9]. Transfected RBL-2H3
cells (2 × 106) were loaded with 1 μM Fura-2 acetoxymethyl ester for 30 min at 37◦C,
followed by de-esterification in HEPES-buffered saline for additional 15 min at room
temperature. Cells were washed, resuspended in 1.5 mL of HEPES-buffered saline
containing 0.1% BSA, and then stimulated with SP. Ca 2+ mobilization was determined
using a Hitachi F-2700 Fluorescence Spectrophotometer with dual excitation wavelength
of 340 and 380 nm, and an emission wavelength of 510 nm.
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3.7. MRGPRX2 Expression and Internalization Assay using Flow Cytometry
Transiently transfected cells were treated with either control (buffer) or SP (30 μM) for 30
minutes to induce receptor internalization. To detect cell surface expression ofMRGPRX2
and its variants’, transfected RBL-2H3 cells (0.5 × 106) were incubated with PEconjugated anti-MRGPRX2 antibody for 30 min at 4◦C in the dark, washed in FACS buffer
(PBS containing 2% FCS and 0.02% sodium azide), and fixed in 1.5% paraformaldehyde.
Cells were acquired using a BD LSR II flow cytometer (San Jose, CA, USA). Results were
analyzed using WinList software, version 8.

3.8. Generation of HTLA cells transiently expressing MRGPRX2 and Y279A variant
HTLA cells (0.8 3 106 cells per well) were plated in a six-well plate in antibiotic-free
medium (DMEM, 10% FBS, and L-glutamine). The following day, the cells were
transfected with MRGPRX2-Tango or Y279A-Tango plasmids using the Lipofectamine
2000 DNA transfection reagent [46]. Briefly, DNA (2 µg) was mixed with Lipofectamine
2000 (12 μl) in Opti-MEM and incubated with cells for 6 h at 37 ̊C. Transfection reagent
was removed, and cells were incubated overnight in antibiotic-free medium. Cells were
used within 16-24 hours. Receptor expression was determined by flow cytometry using
PE-conjugated anti-FLAG Ab.

3.9. Transcriptional activation following arrestin translocation (Tango) assay

HTLA cells transiently expressing either MRGPRX2 or mutant Y279A were plated (50,000
cells per well) on a poly-L-lysine–coated, 96-well, white, clear-bottom cell culture plate in
triplicates in 160 ml of antibiotic-free medium. After 6 h at 37 C
̊ , the medium was
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aspirated, and cells were incubated with SP in 160 μl of antibiotic-free medium for an
additional 16 h at 37 C
̊ . The ligands were aspirated, Bright-Glo solution (100 μl) was
added to each well, and relative luminescence unit was measured in a Thermo
Labsystems Luminoskan Ascent 392 Microplate Luminometer [46].

3.10. Statistical Analysis
Data shown are mean ± standard error of the mean (SEM) values derived from at least
three independent experiments. GraphPad Prism scientific software version 6.07 was
used for statistical analysis. Statistical significance was determined using a
nonparametric t-test. Differences were considered as statistically significant at a value of
* p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001
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4. Results
4.1. Mutation of tyrosine residues Y67A, Y113A, Y137A and Y279A of MRGPRX2
show loss of function phenotype for SP-Induced MC Activation
GPCR database (GPCRdb) was used to recognize amino acid positions in MRGPRX2.
It shows that MRGPRX2 contains six Tyr residues. Five of the tyrosine residues found in
TM domains at positions 2x42, 2x64, 3x36, 6x34 and 7x35. In addition, one is located in
the ICL-2 at position 34x53. Single Ala substitution mutations were made to determine if
these residues affect SP-induced MC activation (Figure 1A, B). We generated transient
transfectants in RBL-2H3 cells expressing WT MRGPRX2 and its variants. All mutants
were expressed in cell surface at a different level (Figure 2). Although MRGPRX2 is
activated by multiple ligands, SP is probably the most well-characterized [9,45]. We
therefore tested the effects of SP on Ca2+ mobilization and degranulation in cells
expressing these variants. Four Tyr mutants Y67A, Y113A, Y137A and Y279A did not
respond to SP for Ca2+ mobilization or degranulation (Figure 3,4). However, The Y89A
and Y222A variants responded normally to SP for Ca2+ mobilization and degranulation
similar to the WT receptor (Figure 3,4).

Due to different levels of expression noted between the WT and the mutants. We
transiently transfected RBL-2H3 cells with lower concentrations of plasmids (0.5 and 1.0
μg) encoding MRGPRX2 and compare it with its variants. Both WT and mutants were
expressed at a comparable level and showed similar responses to the previous
observation regarding MC degranulation and Ca2+ mobilization in response to SP (Figure
5,6 and 7).
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4.2. Mutation of tyrosine residue Y279A of MRGPRX2 Show no receptor
internalization and -arrestin recruitment after stimulation with SP
We selected one tyrosine mutant (Y279A) that was shown previously to display loss of
function phenotype for G protein coupling [45]. First, we measured -arrestin recruitment
by a gene expression assays (Tango). After generating MRGPRX2-Tango plasmid and
Y279A plasmid, we transfected HTLA cells (Human embryonic kidney-293 cell line stably
expressing a tTA-dependent luciferase reporter and a β-arrestin2-TEV fusion gene) with
MRGPRX2-Tango and Y279A-Tango using Lipofection. Then, we measured the relative
luminescence unit. We found that -arrestin was recruited to MRGPRX2 WT; however,
recruitment to Y219A variant was negligible (Fig. 8A). After that, we used flow cytometry
to detect receptor expression of the transfected HTLA cells. We found that MRGPRX2
WT internalized significantly compared to Y279A variant (Fig. 8B). To validate this result,
we transiently transfected RBL-2H3 cells with MRGPRX2 and Y279A mutant, both WT
and the variant were stimulated with SP for 30 min. SP caused a significant (p ≤ 0.001)
reduction in cell surface MRGPRX2 expression compared to the untreated control. By
contrast, mutant Y279A showed no significant effect of SP on cell surface MRGPRX2
expression (Fig. 9A). A representative overlay histogram is shown in (Fig. 9B).
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5. Discussion
The unique characteristics of MRGPRX2 that distinguish it from other GPCRs are its
predominant expression in one subtype MCs and its activation by various groups of
cationic ligands including the neuropeptide SP [45,47]. Receptor mutagenesis has long
been a valuable method to understand different aspects of the mechanisms used by
GPCRs [48]. Our lab recently showed different missense mutants in the MRGPRX2’s
ligand-binding pocket (G165E and D184H) fail to respond to a variety of cationic ligands
including SP, human β-defensin-3, and icatibant (bradykinin B2 antagonist) for receptor
activation [9].

In the present study, we utilized information derived comparison of crystal structures of a
number of class A GPCRs to identify some loss of function variants. These findings have
significant implications for SP/MRGPRX2-mediated conditions such as neurogenic
inflammation, pain, atopic dermatitis, and chronic idiopathic urticaria [27,49,50]. Class A
GPCRs activation is facilitated by extracellular ligands and leads to the recruitment of
intracellular G proteins. Conformational rearrangements of residue contacts in the
transmembrane domain act as ‘activation pathways’ that unite the ligand-binding pocket
to the G protein-coupling region within the receptor. Although there are diverse activation
pathways between receptors, the pathways converge close to the G protein-coupling
region. Analysis was done for the crystals structure of 27 class A, and it was found
rearrangement of contacts involving positions 3x46, 6x37 and 7x53 is likely to be
conserved and important for receptor activation in all class A GPCRs. Residues at
positions 3x46, 6x37, and 7x53 in MRGPRX2 are Val, Isoleucine (Ile), and Tyr,
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respectively. Upon receptor activation, the residue at 3x46 breaks the contact with 6x37
and forms a new contact with 7x53 within the highly conserved NPxxY motif of TM7 [5153]. Given the fact that Tyr at 7x53 plays a critical role in receptor conformational changes
which lead to activation, and to our knowledge no study was conducted specifically to
understand the role of Tyr residues In GPCRs.

MRGPRX2 contains six Tyr residues, five of them located in TM region 2x42, 2x64, 3x36,
6x34, 7x45, and only one in the ICL 34x53. In this current study, we constructed single
Ala substitution mutations at these positions namely, Y67A, Y89A, Y113A, Y137A,
Y222A, and Y279A. Chompunud NA Ayudhya et al. [45] showed that loss of function
phenotype for MC activation by SP in the conserved residue 7x53. Here, we found 3 more
Tyr variants showed the same phenotype 2x42, 3x36 and 34x53 in response to SP.
However, residues at positions 2x64 and 6x34 responded normally to SP in a similar
pattern with the WT. Four missense MRGPRX2 mutants were identified at the expected
G protein coupling sites within the ICL2 [45]. A previous study by our lab showed
MRGPRX2 variant Y137H had no effect on SP-induced MC activation [45]. However, in
this study substitution of Tyr by Ala Y137A in the ICL2 displayed loss of function
phenotype in response to SP. This observation may be explained due to the resemblance
of the amino acid structure of histidine and tyrosine, both of them contain an aromatic
ring.
-arrestins are scaffolding proteins that have a variety of functions including receptor
desensitization, receptor internalization, and induction of downstream signaling pathways
[54]. In 2-AR (Beta-adrenergic receptor), Tyr Y219A is located in the TM5 closer to ICL-
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3 [44]. Choi et al. [44] found that an Ala substitution at Tyr Y219A stimulated G protein–
biased signaling through the 2-AR. In addition, they utilized two different enzyme-based
assays (Tango and DiscoverX) and failed to detect -arrestin recruitment and receptor
internalization which is primarily due to weaken phosphorylation by GRK. In the current
study, the substitution of Tyr by Ala at Y279A of MRGPRX2 failed to detect -arrestin
recruitment and receptor internalization. These findings suggest that a single amino acid
Tyr279 residue is involved in coupling to both G protein and β-arrestin.
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6. Figures

(A)

(B)

Figure 1.

Number
Mutations GPCRdb
*Y67A
2x42
*Y89A
2x64
*Y113A
3x36
*Y137A
34x53
*Y222A
6x34
*Y279A
7x53

Serpentine diagram of the secondary structure of human MRGPRX2. All

tyrosine amino acid residue circled. green, light blue, blue, purple, yellow, and red marks
represent the residues at positions 2x42 (Y67A), 2x64 (Y89A), 3x36 (Y113A), 34x53
(Y137A), 6x34 (Y222A), and 7x35 (Y279A) respectively; (B) Amino acid change for each
MRGPRX2 variant.
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Figure 2.

Effect of mutations at MRGPRX2’s within transmembrane domains (Y67A,

Y89A, Y113A, Y222, and Y279), and in intracellular loop 2 (Y137A) on cell surface
expression. Flow cytometry was used with phycoerythrin (PE)–anti-MRGPRX2 antibody
(AB) to determine cell surface expression of wild-type (WT) and variants in transiently
transfected RBL-2H3 cells. Representative histograms for WT/mutant (blue line) and
control untransfected cells (red line) are shown.

33

Figure 3. Cells expressing WT and MRGPRX2 mutants were loaded with Fura-2 and
intracellular Ca2+ mobilization in response to SP (1 μM) was determined. Data shown are
representative of three independent experiments.
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Figure 4.

Cells were exposed to buffer (control) or SP (1 μM) for 30 min, and β-

hexosaminidase release was determined. All data points are expressed as mean ± SEM
of three experiments performed in triplicate. Statistical significance was determined by
two-tailed unpaired t-test. *p < 0.05.
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Figure 5. Flow cytometry was used with phycoerythrin (PE)–anti-MRGPRX2 antibody
(AB) to determine cell surface expression of wild-type (WT) and variants in transiently
transfected RBL-2H3 cells. Representative histograms for WT/mutant (blue line) and
control untransfected cells (red line) are shown.
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Figure 6.

Cells expressing WT and MRGPRX2 mutants were loaded with Fura-2 and

intracellular Ca2+ mobilization in response to SP (1 μM) was determined. Data shown are
representative of at least three independent experiments.
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Figure 7.

Cells were exposed to buffer (control) or SP (1 μM) for 30 min, and β-

hexosaminidase release was determined. All data points are expressed as mean ± SEM
of three experiments performed in triplicate. Statistical significance was determined by
two-tailed unpaired t test. *p < 0.05.
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(A)

(B)

Figure 8. SP causes -arrestin recruitment and receptor internalization only on the WT
receptor compared to Y279A variant. (A) HTLA cells expressing MRGPRX2-Tango were
incubated, followed by overnight stimulation with SP (30 μM). Effects of SP (30 μM) on
beta-arrestin–mediated gene expression was determined. (B) In HTLA cells, SP a caused
significant (p ≤ 0.005) reduction in cell surface MRGPRX2 expression when compared
with the untreated control, but not variant Y279A, cell surface expression of MRGPRX2
was determined by flow cytometry using anti-MRGPRX2-PE Ab. The data are presented
as mean fluorescent intensity (MFI) of three experiments. ***p < 0.001., ****p < 0.0001.,
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(A)

(B)

Figure 9. SP causes receptor internalization on WT, but not in Y279A variant. (A) RBLMRGPRX2 cells (0.5 x 106) were cultured in for 16 h, both WT and the variant were treated
with SP for 30 minutes. SP caused a significant (p ≤ 0.005) reduction in cell surface
MRGPRX2 expression when compared with the untreated control, but not variant Y279A,
cell surface expression of MRGPRX2 was determined by flow cytometry using antiMRGPRX2-PE Ab. The data are presented as mean fluorescent intensity (MFI) of three
experiments. (B) A representative histogram of cell surface MRGPRX2 receptor
expression is shown. Control (red line) and SP (blue line). ***p < 0.001.
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CHAPTER 3

Expression of MRGPRX2 on Mast Cells of
Patients with Cutaneous Mastocytosis Condition
[Immunohistochemistry/Immunofluorescence]
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Abstract

Mastocytosis is a condition that occurs when MCs accumulate in the skin and/or internal
organs. It is divided into two main categories systemic mastocytosis (SM) and cutaneous
mastocytosis (CM). Urticaria pigmentosa is the most common type of CM that is mainly
presented as generalized small macules and papules of a deep-brown color that affects
the entire body. The etiology of the disease is mainly due to a mutation of a KIT gene.
However, the MCs’ activation mechanism is still unknown. To address this question, we
used immunohistochemistry (IHC) staining to confirm the presence of MCs. After that, we
utilized double immunofluorescence (IF) staining to detect MRGPRX2 signals. We found
that the number of MCs is higher in the diseased samples compared to the control.
Moreover, we detected MRGPRX2 signals in all MCs of patients with urticaria
pigmentosa. Although the mechanism of mastocytosis is still unknown, this is the first
demonstration that MRGPRX2 is expressed at high level in mast cells of patients of
urticaria pigmentosa. These findings may help for further investigation about the role of
MRGPRX2 in this heterogeneous disease.
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1. Introduction
Cutaneous mastocytosis (CM)
Definition and types
Cutaneous mastocytosis is a condition where MCs accumulate in the skin [39,55]. There
are several clinical forms of CM, the maculopapular cutaneous mastocytosis (MPCM)
which is known as “urticaria pigmentosa”, diffuse cutaneous mastocytosis (DCM), and
mastocytoma of the skin (MS) [55]. Cutaneous mastocytosis can be diagnosed clinically
and confirmed via histopathological examination of the diseased skin. There are several
clinical pictures of CM. These manifestations are highly heterogeneous, varying from
localized reddening and swelling to more generalized and disseminated forms such as
pruritus, flushing, and blistering [39,55]. Histologically, skin sample of a patient with CM
show significant accumulation of spindle-shaped and round MCs compared to the healthy
normal skin [56].

Maculopapular cutaneous mastocytosis (MPCM) “Urticaria Pigmentosa”
The term, urticaria, was first described by Johann P Frank in 1792 [55]. It is considered
the most common cutaneous form of mastocytosis in both adults and children [39,57,58].
Earlier, urticaria (with or without angioedema) was classified as acute or chronic [55].
Chronic urticaria is defined as daily or almost daily urticaria for more than 6 weeks.
However, if the history of the lesion is less than 6 weeks is termed acute urticaria [55].
Traditionally, Chronic urticaria has been subdivided into physical urticaria (wheals evoked
by a physical stimulus, such as pressure, friction, cold contact, or sun exposure) and
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spontaneous urticaria [55]. Moreover, Chronic urticaria may be aggravated by anxiety and
stress, raising the likelihood of a neurogenic component in its pathophysiology [56,58]. In
2016, the task force involving experts from different organizations (including the European
Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &
Immunology; and the European Academy of Allergology and Clinical Immunology)
reported a classification of urticaria pigmentosa based on the age of the patient. They
recommend that urticaria pigmentosa should be subdivided into 2 forms, namely a
monomorphic variant that is characterized by small maculopapular lesions, which is
usually seen in adult patients, and a polymorphic variant with bigger lesions of variable
size and shape, which is typically seen in children [32]. It has been shown that the
monomorphic variant, if it develops in pediatric patients, often continues into adulthood,
however, the polymorphic variant may resolve around puberty [39]. The lesion can be
presented clinically in different forms such as indistinct, sharp margins, elevated and flat
lesions [39]. In most adult patients with urticaria pigmentosa, MC infiltrates are also found
in the bone marrow, consistent with the final diagnosis of SM (most commonly ISM) [39].
However, it is rare that adult patients with maculopapular lesions do not display systemic
involvement and therefore represent cases with true MPCM [39]. The task force
anticipated that almost 95% of patients with ISM exhibit maculopapular skin lesions
compared with around 50% of patients with advanced SM [39]. Clinically, Itch is the most
common symptom of urticaria. Most patients with urticaria rub rather than scratch their
itchy wheals [56]. Darier’s sign is considered one of the most specific diagnostic features
of CM, it is a wheal-and-flare reaction that develops upon stroking of a CM lesion [39].
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Histology and immunohistochemistry
Skin lesion of patients with CM show up to 20-fold increase in the number of MCs
compared to skin obtained from healthy subjects [39,56,59]. However, a variation is
noticed in number of dermal MCs between patients exhibiting either similar or different
types of mastocytosis [56]. It has been shown that DCM and MS show a higher number
of MCs compared to MPCM [56]. Moreover, children with polymorphic variant of MPCM
display greater MC number compared to adults with monomorphic variant [60].
Additionally, MC number is affected by the anatomical site, for example, the face has
more MCs compared to the trunk, and superficial layers of the dermis shows more MCs
than deeper layers [39]. Mast cells in skin lesions can be round or spindle shaped. It has
been shown that MCs in adult patients with monomorphic MPCM variant tend to be
spindle shaped, whereas in children with polymorphic lesions is mainly spherical [39].

Different types of staining were known to detect MCs, such as Giemsa and toluidine blue;
however, the task force recommended the use of an antibody against tryptase as a gold
standard to detect and quantify MCs [39,61].

CM is considered a complex disease due to the heterogeneity of both clinical and
histological conditions. The activation of MCs in this disorder is still not fully understood.
Thus, we decided to address this question by determining if MRGPRX2 is expressed in
skin MCs of patients with urticaria pigmentosa.
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2. Research Aim
To determine if MRGPRX2 is expressed on MCs of patient with mastocytosis utilizing
Immunohistochemistry/Immunofluorescence techniques.

3. Materials and Methods

3.1 Sample Collection

Skin tissue samples embedded in paraffin were received from Dr. Dean Metcalfe
and Dr. Hirsh Komarow from the National Institute of Allergy and Infectious Diseases
(NIAID) at the National Institutes of Health (NIH). Samples include skin from normal
healthy subjects and diseased tissue obtained from patients diagnosed with Urticaria
Pigmentosa, Cholinergic Urticaria, Delayed Pressure, Cold Urticaria and Vibratory
Urticaria.

3.2 Materials

Purified anti-human MRGPRX2, catalog # 359002 was purchased from Biolegend
(San Diego, CA). Rabbit anti-human tryptase, catalog #: ab134932 was purchased
from abcam (Cambridge, MA). Mouse anti-human tryptase, catalog #: sc-33676 was
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purchased from Santa Cruz (Dallas, TX). Goat anti-rabbit secondary antibody, Alexa
Fluor 488, catalog #: A-11008 was purchased from ThermoFisher Scientific (Grand
Island, NY). Donkey anti-rabbit secondary antibody, Alexa Fluor 594, catalog #:
A21207 was purchased from ThermoFisher Scientific (Grand Island, NY). Donkey
anti-mouse secondary antibody Alexa Fluor 647, catalog #: A31571 was purchased
from ThermoFisher Scientific (Grand Island, NY). 4’,6-diamidino-2-phenylindole
(DAPI) was obtained from Invitrogen (Grand Island, New York). ProLong Gold
antifade reagent was purchased from Invitrogen (Grand Island, NY). Target retrieval
solution was purchased from Dako (Carpinteria, CA). Mouse IgG Vectastain ABC kit,
catalog #: PK-4002 was purchased from Vector Laboratories (Burlingame, CA). 3,3’diaminobenzidine (DAB) peroxidase substrate kit, catalog #: SK-4100 was
purchased from Vector Laboratories (Burlingame, CA).

3.3 Methods

3.3.1. Immunohistochemistry

Immunohistochemistry (IHC) experiments were performed on human normal and
diseased skin. Tissue samples were embedded in paraffin. The slides were heated
to 55oC overnight, subsequently deparaffinized in Histoclear and hydrated in a
series of graded ethanol incubations. Antigen retrieval was performed by heat
treatment using 1X antigen retrieval solution in a water bath at 95 oC for 1hour. The
slides were placed in a humidified chamber and peroxidase quenching was achieved
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with 0.3% H2O2 blocking solution for 10 min at room temperature followed by 2
washes in PBS. The slides were incubated for 1 hour at room temperature with
blocking serum using normal donkey serum followed by incubation with primary
antibody (anti-human tryptase) at a dilution of 1:1000 overnight at 4oC in a
humidified chamber. For negative control, serum blocking reagent was used in place
of primary antibody on the first section of all slides. The sections were then washed
3 times with PBS/0.1% Tween and incubated with diluted secondary antibody,
biotinylated horse anti mouse IgG for 30 minutes at room temperature. Following
incubation with secondary antibody, they were washed 3 times in PBS/0.1% Tween
and incubated for 30 minutes with Vectastain ABC reagent. Subsequently, they were
washed 3 times in PBS/0.1% Tween and incubated in peroxidase substrate solution
using DAB peroxidase substrate kit until desired color intensity was observed. The
slides were rinsed under running tap water for 5 minutes, counterstained in Mayer’s
hematoxylin solution for 30 seconds and rinsed again in running tap water until
excess solution was removed. Rehydration of the tissue was done using increasing
graded alcohol series followed by Histoclear solution. The slides were allowed to air
dry before mounting with Permount mounting medium. Images were captured on a
Nikon Eclipse microscope.
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3.3.2. Immunofluorescence

Immunofluorescence (IF) experiments were performed on the same tissue samples
as IHC experiments. Tissue deparaffinization were performed as described above
for IHC. The tissue samples were subsequently incubated with blocking buffer [5%
normal donkey serum, 0.3% of Triton X-100 in phosphate buffered saline (PBS)] for
1 hour at room temperature. Incubation with first primary antibody (anti-human
tryptase 1:1000) and second primary antibody (anti-human MRGX2 1:200) was
carried out in antibody dilution buffer (PBS with 1% bovine serum albumin and 0.3%
Triton X-100) overnight at 4oC. For negative control, antibody dilution buffer was
used in place of primary antibody on the first section of all slides. The sections were
then washed 3 times with PBS and incubated with first secondary antibody,
Alexafluor 488-conjugated goat anti-rabbit (1:400), second secondary antibody in
conjunction with DAPI (1:1000) for 1 hour at room temperature in the dark. Tissue
sections were washed 3 times with PBS and incubated overnight at 4 oC with antihuman MrgX2 primary antibody at a dilution of 1:200. The sections were again
washed 3 times with PBS and incubated in the dark at room temperature with
secondary antibody, Alexa flour 647-conjugated donkey anti-mouse at a dilution of
1:400. The tissues were washed 3 times in PBS and mounted with ProLong Gold
antifade reagent. Images were captured on a Nikon Eclipse microscope with an
Olympus digital microscope camera using 20X and 40X objectives.
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4. Results
4.1 Expression of MRGPRX2 in skin samples of patients with urticaria
pigmentosa.
Our goal here was to determine if MCs from patients with urticaria pigmentosa express
MRGPRX2. For all human skin tissue samples, we utilized two approaches to study
MCs and MRGPRX2. First, we used IHC with an anti-tryptase antibody to determine the
presence of MCs in relation to structural cells in the skin. Second, we used a double IF
staining approach to determine the expression of MRGPRX2 (red), MCs (green) in the
context of the nucleus (blue). Using IHC, we found that MCs are present in the dermal
layers in both healthy and diseased skin tissue compared to the epidermis (Figure 1).
Using IF, we found that MRGPRX2 is expressed in urticaria pigmentosa skin samples
(Fig. 2A and B). When the MRGPRX2 and tryptase panels were merged, it clearly
showed that MCs in mastocytosis skin samples express MRGPRX2. Interestingly, two
of the lesioned samples that were obtained from adult patients with urticaria pigmentosa
exhibited spindle-shaped mast cells that colocalized with the red color of MRGPRX2
(Figure 3). Using IHC and IF, we quantitated the number of MCs in both healthy and
diseased tissues. We found that the number of MCs was different in skin tissues from
control subjects compared with urticaria pigmentosa patients (Figure 4A and B).
Moreover, we found variation in the number of MCs between the diseased samples as
well (Figure 4A and B). Given the fact that MRGPRX2 was expressed in diseased
samples with mastocytosis, it may play a role in this heterogenous diseased.
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5. Discussion
Cutaneous mastocytosis is considered a heterogeneous disorder in both clinical and
histopathological aspects [39,56,58]. Clinically, it manifests as single nodular, multiple
lesions, or as a generalized diffuse lesion that affects almost the entire skin [56]. The
latter is the common presentation of urticaria pigmentosa [56]. Urticaria pigmentosa is the
most common variant of CM. Moreover, most patient with ISM showed cutaneous
manifestations [32,39,56,58]. Thus, we should consider examining patients for SM in
case they exhibited any cutaneous lesion. The histopathological aspect of all lesions of
CM is an infiltrate by MCs that can be recognized under the microscope. Different basic
dyes were utilized to detect MCs such as Giemsa, toluidine blue and Astra blue; however,
using immunohistochemical stains provides more accurate picture of MCs [56,62]. In this
study, we utilized anti-tryptase antibody to detect MCs. We noticed the presence of MCs
in both healthy and urticaria pigmentosa samples; however, more MCs infiltrates
observed in the diseased samples. Interestingly, we noted also a variation in the number
of MCs between the diseased samples, which reflected the complexity of the disease.
The activation of MCs in mastocytosis condition is still unknown. Thus, we decided to
examine the diseased samples microscopically via double IF staining using both tryptase
and MRGPRX2 antibodies. We noticed that MRGPRX2 was expressed in all MCs in the
diseased samples. It is possible that host defense peptides released from keratinocytes
and neuropeptides from peripheral nerve endings and other cells activate mast cells via
MRGPRX2 to contribute to urticaria pigmentosa. This finding can help us to understand
the unidentified aspects of this disease.
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Different studies showed that patients with CM showed spherical or round MCs.
Furthermore, adult patients were found to have more spindle shaped MCs compared to
children. In this study, we observed spindle-shaped MCs in two of the samples with the
same disease, which again reflects the heterogeneity of the disease.
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6. Tables and Figures
Table 1:
World Health Organization (WHO) classification of mastocytosis [32].
Adapted from: Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel
emerging treatment concepts. Blood, The Journal of the American Society of Hematology
2017;129(11):1420-1427.

Cutaneous Mastocytosis
A. Maculopapular cutaneous mastocytosis = Urticaria pigmentosa
1. Monomorphic variant [mainly in adults]
2. Polymorphic variant [mainly in children]

B. Diffuse cutaneous mastocytosis
C. Mastocytoma of skin (cutaneous mastocytoma)

Systemic Mastocytosis
A. Indolent systemic mastocytosis
B. Smoldering systemic mastocytosis
C. Systemic mastocytosis with an associated hematologic (non-MC lineage) neoplasm
D. Aggressive systemic mastocytosis
E. Mast cell leukemia
F. Mast cell sarcoma
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Table 2:
World Health Organization (WHO) diagnostic criteria for systemic mastocytosis (SM) [32].
Adapted from: Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel
emerging treatment concepts. Blood, The Journal of the American Society of Hematology
2017;129(11):1420-1427.

Major Systemic Mastocytosis Criterion
Multifocal dense infiltrates of mast cells (≥15 MCs in aggregates) in bone marrow biopsies
and/or in sections of other extracutaneous organ(s)

Minor Systemic Mastocytosis Criteria
A. >25% of all mast cells are atypical cells (type I or type II) on bone marrow smears or are
spindle-shaped in mast cell infiltrates detected on sections of visceral organs
B. KIT point mutation at codon 816 in the BM or another extracutaneous organ
C. Mast cells in bone marrow or blood or another extracutaneous organ exhibit CD2 and/or
CD25
D. Baseline serum tryptase level >20 ng/mL (in case of an unrelated myeloid neoplasm, item
D is not valid as a systemic mastocytosis criterion)
If at least 1 major and 1 minor or 3 minor SM criteria are fulfilled, the diagnosis of SM can be established
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Figure 1. Mast Cells presented in both healthy skin and patients with urticaria
pigmentosa. IHC was performed on human skin tissue obtained from healthy control
and patients diagnosed with urticaria pigmentosa using the MC marker tryptase. Note
dark brown cytoplasmic staining of MCs. Most MCs were observed in the dermal layers
in both healthy and diseased skin tissue compared to the epidermis.

55

(A)
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(B)

Figure 2. MRGPRX2 is expressed in skin MCs of patients with urticaria pigmentosa.
(A, B) Double IF staining was performed on human skin tissue with urticaria
pigmentosa. MRGPRX2 is shown in (red), tryptase in (green) and the nuclei (blue). Note
that there is a colocalization of MRGPRX2 and tryptase in all MCs of patients with
urticaria pigmentosa. Images taken at 20x and 40X magnification using a Nikon Eclipse
fluorescent microscope.
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(A)
DAPI

MRGPRX2

Tryptase

Tryptase + MRGPRX2

Tryptase + MRGPRX2 + DAPI

(B)

Figure 3. This sample was obtained from an adult patient with urticaria pigmentosa.
(A) It shows spindle shaped mast cells that colocalized with the red color of MRGPRX2.
(B) same sample stained for both IHC and IF. Images taken at 20x and 40X
magnification using a Nikon Eclipse fluorescent microscope
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(A)

(B)

Figure 4. IHC and IF staining of both healthy and diseased (urticaria pigmentosa)
samples. (A, B) Healthy sample shows a smaller number of MCs compared to diseased
samples. Note that there is a discrepancy in the number of MCs between the two
diseased samples

59

7. Conclusion and Future Direction

•

We found that Two Tyr variants (Y89A and Y222A) responded normally to SP for
degranulation and Ca2+ mobilization. However, four Tyr variants (Y67A, Y113A,
Y137A, and Y279A) were unresponsive. Moreover, Tyr variant Y279A failed to
recruit -arrestin and internalize in response to SP. These findings may indicate
that Tyr 7x53 within the NPxxY motif of TM7 has the affinity to couple to both Gprotein and β-arrestin. Next, Proximity ligation assay will be performed to
determine the direct receptor-G protein activation. Additionally, a confocal
microscopy will be used to determine the receptor internalization which reflects the
direct receptor--arrestin interaction.

•

The other finding, we demonstrated for the first time that MRGPRX2 is expressed
on MCs of patients with urticaria pigmentosa. Next, we will measure and compare
the intensity of tryptase and MRGPRX2 signals in both health and diseased
samples using a confocal microscopy. After that, the RNA will be extracted from
the paraffin-embedded tissue, and qRT-PCR will be performed to measure and
compare the expression levels of both tryptase and MRGPRX2.
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